• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
    • Corporate Videos
  • Development Programs
    • Biopharmaceutical Trials
    • Group Strategy and Target Markets
    • NTI164
    • Clinical Trials
    • Pathways to Commercialisation
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Investor Conference Calls  
    • Company Reports
    • Presentations
    • Research
    • News & Media
    • Fact Sheets
    • Analyst Reports
    • Right to Receive Documents
  • Contact

Improving Lives

Focusing on the development and commercialisation of NTI164 for multiple paediatric neurological disorders

Learn More

ASX:NTI

Exclusive worldwide licence

Extensive preclinical studies completed

Potent anti-neuroinflammatory effects with NTI164

Paediatric Focus

NTI164 to be regulated as prescription-only drug

Patents Pending

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety.

In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

Learn More

Watch our new Corporate Video here

Bioshares Report
Now Available

Neurotech International (NTI: $0.071) has released the results from its Phase II study in children with moderate autism spectrum disorder (ASD). The study involved 14 children who were treated with lead drug candidate, NTI164.

Read Full Report

Latest Announcements

View All

Latest News

  • Neurotech International: NWR Virtual Healthcare Conference with Dr Thomas Duthy

    24 Mar 2024
  • Neurotech International Ltd Extends Rett Syndrome Study With Novel Cannabinoid Drug

    13 Mar 2024
  • Neurotech extends clinical trials for the $US2bn Rett Syndrome market

    13 Mar 2024
  • Neurotech International extends NTI164 Rett Syndrome trial to 52 weeks

    13 Mar 2024

View All

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1749696702anoit1749696702anret1749696702nihce1749696702torue1749696702n@ofn1749696702i1749696702

+61 (8) 9389 3130

Subscribe to our latest announcements

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2025 Neurotech International • Site by White Noise Communications

Download prospectus